This is a fourth generation fluoroquinolone antibacterial agent developed by Bayer AG. It is being marketed as hydrochloride all over the world. This drug is also available in the parental form and is used for intravenous infusion. It is also available in ophthalmic solution to be used as eye drop under the drug class names Vigamox and Moxeza. In this form, it is being used for the cure of problems like Conjunctivitis.It is much better than levofloxacin and ciprofloxacin and has greater activitythan gram bacteria and anaerobes. It is also known for its potent activity against the common respiratory pathogens streptococcus pneumonia and that is why it is known as respiratory quinolone. The first patent named Avelox was released in 1989 in US and its use was approved in 1999 for use in US. It is generally used for cure of bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired bacterial, complicated and uncomplicated form of skin and skin structure infection and intra-abdominal infections. There are various side effects and it might lead to liver toxicity and skin reactions, which has led to restrictions in various parts of Europe.